Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

Tools

Item Type:	Article
Title:	Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas
Creators Name:	Jacobs, A., Voges, J., Reszka, R., Lercher, M., Gossmann, A., Kracht, L., Kaestle, C., Wagner, R., Wienhard, K. and Heiss, W.D.
Abstract:	In clinical gene-therapy trials for recurrent glioblastomas, transduction of the herpes simplex virus type-1 thymidine kinase (HSV-1-tk) gene with subsequent prodrug activation by ganciclovir was found to be safe, but clinical response was poor. We used positron-emission tomography (PET) with I-124-labelled 2'-fluoro-2'-deoxy-1{beta}-D-arabino-furanosyl-5-iodo-uracil ([ 124I]-FIAU) - a specific marker substrate for gene expression of HSV-1-tk - to identify the location, magnitude, and extent of vector-mediated HSV-1-tk gene expression in a phase I/II clinical trial of gene therapy for recurrent glioblastoma in five patients. The extent of HSV-1-tk gene expression seemed to predict the therapeutic response. The expression of an exogenous gene introduced by gene therapy into patients with gliomas can be monitored non-invasively by PET.
Keywords:	Antiviral Agents, Arabinofuranosyluracil, Emission-Computed Tomography, Gene Therapy, Genetic Transduction, Glioblastoma, Human Herpesvirus 1, Local Neoplasm Recurrence, Predictive Value of Tests, Thymidine Kinase, Viral Gene Expression Regulation
Source:	Lancet
ISSN:	0140-6736
Publisher:	Lancet
Volume:	358
Number:	9283
Page Range:	727-729
Date:	1 January 2001
Official Publication:	https://doi.org/10.1016/S0140-6736(01)05904-9
PubMed:	View item in PubMed

Repository Staff Only: item control page